We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott Outpaces Peers Defying Tariff Woes: Is ABT Stock a Smart Buy?
Read MoreHide Full Article
Despite facing a challenging industry-wide investment climate driven by tariffs, Abbott (ABT - Free Report) has managed to achieve an 18.8% gain so far in 2025, outperforming the industry, its benchmark, and the company’s main competitors. During this period, while the broader Medical Products industry grew 5.5%, the S&P 500 index declined 3.8%.
Year to date, the company’s archrivals like Boston Scientific (BSX - Free Report) and Medtronic (MDT - Free Report) have risen 16.6% and 3.9%, respectively.
ABT YTD Price Comparison
Image Source: Zacks Investment Research
Tariff Pressure Clouds Overall Medical Device Outlook
The escalating tariff environment is beginning to weigh heavily on the financial outlook of key MedTech players, with Abbott, Boston Scientific and Medtronic all facing varying degrees of exposure. Abbott expects “a few hundred million dollars” in tariff-related costs for 2025, which it currently considers manageable. However, its reliance on a global supply chain and imported high-margin devices could lead to rising cost pressure from the third quarter onward. While strong early-year performance offers a buffer, prolonged tariffs pose risks to margins and supply chain stability.
Boston Scientific, on the other hand, expects a $200 million tariff impact in 2025 but aims to offset it through sales growth, spending cuts and a minor FX gain. With reaffirmed EPS guidance and margin expansion plans, Boston Scientific shows operational confidence. However, the delayed tariff impact in the second half may challenge its ability to maintain momentum and cost discipline.
Medtronic, with a major manufacturing presence in Mexico and Canada, is perhaps the most geopolitically entangled. The upcoming May 21 earnings release may shed light on how exposed the company is to cross-border tariff disruptions. Given its diverse portfolio, which ranges from insulin delivery systems to surgical robots, Medtronic could face not only higher production costs but also potential delays in market access if retaliatory tariffs or regulatory bottlenecks emerge.
Defensive Strategy Might Improve Situation
Despite trade policy challenges, Abbott’s global footprint and 90 manufacturing sites offer flexibility to manage regional risks and reroute supply chains. Management is exploring long-term strategies to reduce tariff exposure, including localizing production, optimizing supplier contracts, while potentially offsetting costs through pricing adjustments.
Long-Term Takeaways of Abbott Impress
Abbott’s Diagnostics segment, accounting for 20% of first-quarter 2025 revenues, is showing strong long-term growth potential, driven by rising global demand for routine testing, particularly for respiratory diseases like flu, strep, and RSV across diverse healthcare settings. A recent major account win supports continued momentum. Core Lab Diagnostics (excluding China) grew 6.5% in the first quarter. Abbott’s $0.5 billion investment in new manufacturing and R&D facilities in Illinois and Texas aims to expand its U.S. transfusion diagnostics business. Moreover, the upcoming launch of the Alinity m system marks Abbott's entry into the molecular nucleic acid testing segment — a $1 billion market opportunity.
Within Established Pharmaceuticals Division (EPD), the company is progressing strategically. EPD operates solely in emerging geographies, with leading positions in many of the largest and fastest-growing pharmaceutical markets for branded generics in the world. Banking on the successful execution of its Branded Generic operating model, EPD is well-positioned for sustained growth in many of these growing pharmaceutical markets. Focusing on the therapies most needed in the faster-growing markets, Abbott continues to sustain its long track record of delivering strong growth, which includes a five-year CAGR for EPD of 8%. Further, Abbott’s strategic focus on biosimilars strengthens its prospects, with the company now securing rights to 15 biosimilar products across key therapeutic areas.
Abbott’s Medical Devices business also shows strong long-term growth potential, supported by solid sales across key areas. Diabetes Care led the way with more than 20% growth in glucose monitors, especially in the United States. Structural Heart and Electrophysiology also posted strong gains, helped by the early launch of the Volt PFA system and increasing use of TriClip. Abbott is expanding in Heart Failure with broader coverage for CardioMEMS and growing its Vascular business with new trials like its coronary lithotripsy system. The company is also entering new markets, such as neuromodulation for treatment-resistant depression, a $1 billion opportunity.
Overall, Abbott’s innovation and broad product portfolio position it well for future growth.
ABT's High Return on Equity
ABT’s trailing 12-month return on equity (ROE) of 19.01% outpaces the average earned by companies in the Medical Products industry (17.15%). This superior ROE underscores Abbott’s efficient management and ability to generate strong returns for shareholders, further reinforcing its investment appeal.
Image Source: Zacks Investment Research
Further, Abbott is currently trading above both its 50-day simple moving average (SMA) and 200-day SMA. Despite its short-term bearishness in the form of macro complexities, this technical setup indicates that the stock is performing well in both the short and long term. These favorable SMAs may now serve as important support levels, providing a cushion against potential price pullbacks due to external pressure.
50- and 200-Day SMAs
Image Source: Zacks Investment Research
Stretched Valuation
From a valuation standpoint, Abbott’s forward 12-month price-to-earnings (P/E) is 24.96X, a premium to the industry average of 21.54X.
The company is also trading at a significant premium to industry players like Medtronic, with its current P/E being 14.1. However, Boston Scientific, with a current P/E of 34.34X, appears more stretched.
Image Source: Zacks Investment Research
Hold Abbott Stock Now
Despite its adaptive strategies, Abbott's stock price has not fully reflected the company’s underlying strength. The subdued market reaction to its positive first-quarter results suggests that investors remain cautious amid geopolitical uncertainty, mainly in the form of retaliating tariffs.
The current stretched valuation suggests that investors may be paying a higher price relative to the company's expected earnings growth. While the impressive performance in the first quarter boosted investor sentiment, this might not be the ideal time to invest in Abbott. The short-term hiccups in the form of international trade challenges are limiting the stock’s near-term gains.
Accordingly, while current shareholders should hold their positions, new investors should wait for a better entry point.
Image: Bigstock
Abbott Outpaces Peers Defying Tariff Woes: Is ABT Stock a Smart Buy?
Despite facing a challenging industry-wide investment climate driven by tariffs, Abbott (ABT - Free Report) has managed to achieve an 18.8% gain so far in 2025, outperforming the industry, its benchmark, and the company’s main competitors. During this period, while the broader Medical Products industry grew 5.5%, the S&P 500 index declined 3.8%.
Year to date, the company’s archrivals like Boston Scientific (BSX - Free Report) and Medtronic (MDT - Free Report) have risen 16.6% and 3.9%, respectively.
ABT YTD Price Comparison
Image Source: Zacks Investment Research
Tariff Pressure Clouds Overall Medical Device Outlook
The escalating tariff environment is beginning to weigh heavily on the financial outlook of key MedTech players, with Abbott, Boston Scientific and Medtronic all facing varying degrees of exposure. Abbott expects “a few hundred million dollars” in tariff-related costs for 2025, which it currently considers manageable. However, its reliance on a global supply chain and imported high-margin devices could lead to rising cost pressure from the third quarter onward. While strong early-year performance offers a buffer, prolonged tariffs pose risks to margins and supply chain stability.
Boston Scientific, on the other hand, expects a $200 million tariff impact in 2025 but aims to offset it through sales growth, spending cuts and a minor FX gain. With reaffirmed EPS guidance and margin expansion plans, Boston Scientific shows operational confidence. However, the delayed tariff impact in the second half may challenge its ability to maintain momentum and cost discipline.
Medtronic, with a major manufacturing presence in Mexico and Canada, is perhaps the most geopolitically entangled. The upcoming May 21 earnings release may shed light on how exposed the company is to cross-border tariff disruptions. Given its diverse portfolio, which ranges from insulin delivery systems to surgical robots, Medtronic could face not only higher production costs but also potential delays in market access if retaliatory tariffs or regulatory bottlenecks emerge.
Defensive Strategy Might Improve Situation
Despite trade policy challenges, Abbott’s global footprint and 90 manufacturing sites offer flexibility to manage regional risks and reroute supply chains. Management is exploring long-term strategies to reduce tariff exposure, including localizing production, optimizing supplier contracts, while potentially offsetting costs through pricing adjustments.
Long-Term Takeaways of Abbott Impress
Abbott’s Diagnostics segment, accounting for 20% of first-quarter 2025 revenues, is showing strong long-term growth potential, driven by rising global demand for routine testing, particularly for respiratory diseases like flu, strep, and RSV across diverse healthcare settings. A recent major account win supports continued momentum. Core Lab Diagnostics (excluding China) grew 6.5% in the first quarter. Abbott’s $0.5 billion investment in new manufacturing and R&D facilities in Illinois and Texas aims to expand its U.S. transfusion diagnostics business. Moreover, the upcoming launch of the Alinity m system marks Abbott's entry into the molecular nucleic acid testing segment — a $1 billion market opportunity.
Within Established Pharmaceuticals Division (EPD), the company is progressing strategically. EPD operates solely in emerging geographies, with leading positions in many of the largest and fastest-growing pharmaceutical markets for branded generics in the world. Banking on the successful execution of its Branded Generic operating model, EPD is well-positioned for sustained growth in many of these growing pharmaceutical markets. Focusing on the therapies most needed in the faster-growing markets, Abbott continues to sustain its long track record of delivering strong growth, which includes a five-year CAGR for EPD of 8%. Further, Abbott’s strategic focus on biosimilars strengthens its prospects, with the company now securing rights to 15 biosimilar products across key therapeutic areas.
Abbott’s Medical Devices business also shows strong long-term growth potential, supported by solid sales across key areas. Diabetes Care led the way with more than 20% growth in glucose monitors, especially in the United States. Structural Heart and Electrophysiology also posted strong gains, helped by the early launch of the Volt PFA system and increasing use of TriClip. Abbott is expanding in Heart Failure with broader coverage for CardioMEMS and growing its Vascular business with new trials like its coronary lithotripsy system. The company is also entering new markets, such as neuromodulation for treatment-resistant depression, a $1 billion opportunity.
Overall, Abbott’s innovation and broad product portfolio position it well for future growth.
ABT's High Return on Equity
ABT’s trailing 12-month return on equity (ROE) of 19.01% outpaces the average earned by companies in the Medical Products industry (17.15%). This superior ROE underscores Abbott’s efficient management and ability to generate strong returns for shareholders, further reinforcing its investment appeal.
Image Source: Zacks Investment Research
Further, Abbott is currently trading above both its 50-day simple moving average (SMA) and 200-day SMA. Despite its short-term bearishness in the form of macro complexities, this technical setup indicates that the stock is performing well in both the short and long term. These favorable SMAs may now serve as important support levels, providing a cushion against potential price pullbacks due to external pressure.
50- and 200-Day SMAs
Image Source: Zacks Investment Research
Stretched Valuation
From a valuation standpoint, Abbott’s forward 12-month price-to-earnings (P/E) is 24.96X, a premium to the industry average of 21.54X.
The company is also trading at a significant premium to industry players like Medtronic, with its current P/E being 14.1. However, Boston Scientific, with a current P/E of 34.34X, appears more stretched.
Image Source: Zacks Investment Research
Hold Abbott Stock Now
Despite its adaptive strategies, Abbott's stock price has not fully reflected the company’s underlying strength. The subdued market reaction to its positive first-quarter results suggests that investors remain cautious amid geopolitical uncertainty, mainly in the form of retaliating tariffs.
The current stretched valuation suggests that investors may be paying a higher price relative to the company's expected earnings growth. While the impressive performance in the first quarter boosted investor sentiment, this might not be the ideal time to invest in Abbott. The short-term hiccups in the form of international trade challenges are limiting the stock’s near-term gains.
Accordingly, while current shareholders should hold their positions, new investors should wait for a better entry point.
Abbott currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.